Q4 2025 Grail Inc Earnings Call Transcript
Key Points
- GRAIL Inc (GRAL) reported a 14% increase in fourth-quarter revenue compared to Q4 2024, driven by a 34% rise in screening revenue.
- The U.S. Galleri test volume grew by 36% in 2025, with revenue increasing by 26%, indicating strong market demand.
- The NHS Gallery trial showed a substantial reduction in Stage I cancer diagnoses and a fourfold increase in overall cancer detection rates.
- GRAIL Inc (GRAL) completed its PMA submission to the FDA, marking a critical step towards broader access to its Galleri test.
- The company is in a strong financial position with over $900 million in cash, providing a solid runway for future growth and expansion.
- The NHS Gallery trial did not meet its primary endpoint of statistically significant reduction in combined Stage III and IV cancers.
- GRAIL Inc (GRAL) reported a net loss of $99.2 million for Q4 2025, an increase compared to the previous year.
- Development services revenue decreased by 49% from 2024, indicating challenges in that segment.
- The company anticipates royalty payments to Illumina starting in 2027, which may impact future gross margins.
- There is uncertainty regarding the impact of the NHS Gallery trial results on FDA approval and Medicare coverage decisions.
Good day, ladies and gentlemen, and welcome to the GRAIL fourth-quarter 2025 earnings call. (Operator Instructions) Please be advised that this conference call is being recorded. GRAIL Investor Relations, please begin.
Thank you, operator, and thank you all for joining us today. On the call are Bob Ragusa, our Chief Executive Officer; Aaron Frieden, our Chief Financial Officer; Josh Ofman, President; Sir Harpal Kumar, Chief Scientific Officer and President, International; and Andy Partridge, Chief Commercial Officer. Before we get underway, I'll remind you that we'll be making forward-looking statements based on current expectations.
It's our intent that all statements, other than statements of historical fact, including statements regarding our anticipated financial results and commercial activity will be covered by the safe harbor provisions for forward-looking statements under federal securities laws. Forward-looking statements are subject to risks and uncertainties and -- actual events or results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
